Depemokimab (Exdensur®) for Severe Eosinophilic Asthma in Patients 12 Years and Older
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for depemokimab (Exdensur) as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma characterized by an eosinophilic phenotype and inadequately controlled by medium-to high-dose inhaled corticosteroids (ICS) plus another asthma controller.